Monocyte deactivation in neutropenic acute respiratory distress syndrome patients treated with granulocyte colony-stimulating factor

Table 2 Cytokine production at baseline and after lipopolysaccharide induction for neutropenic patients and for non-neutropenic patients and control individuals

Cytokine	Control individuals (n = 10)	Non-neutropenic patients (n = 12)	Neutropenic patients (n = 10)
Spontaneous production
TNFα	25 (10–50)	100 (10–400)^*†	10 (10–10)
IL-1	20 (15–45)	30 (15–870)	15 (15–15)
IL-6	85 (10–115)	5,580 (20–19,560)^*†	45 (9–61)
IL-1 receptor antagonist	205 (90–920)	5,740 (430–9,660)^*†	175 (74–713)
IL-10	15 (5–45)	50 (5–870)^*†	5 (5–5)
Lipopolysaccharide-induced production
TNFα	280 (125–970)^*‡	1,830 (560–3,570)^*†‡	10 (10–10)
IL-1	855 (105–1,550)^*‡	7,900 (410–9,120)^*†‡	15 (15–15)
IL-6	6205 (520–8,825)^*‡	53,720 (13,800–79,450)^*†‡	720 (3–1,113)
IL-1 receptor antagonist	1045 (340–2,250)^*‡	19,110 (5,785–39,110)^*†‡	335 (180–780)
IL-10	305 (70–805)^*‡	1,875 (290–3,280)^†‡	5 (5–5)

Data (pg/ml) are expressed as the median and quartile (25th–75th percentiles). P < 0.05 was considered significant: *P < 0.05 versus neutropenic patients, using the Mann–Whitney U test; ^†P < 0.05 versus control individuals, using the Mann–Whitney U test; and ^‡P < 0.05 baseline versus lipopolysaccharide conditions, using the Wilcoxon test.

ISSN: 1364-8535